Jiangsu Hengrui Medicine Co., Ltd.

SHSE:600276 Stock Report

Market Cap: CN¥283.9b

Jiangsu Hengrui Medicine Future Growth

Future criteria checks 1/6

Jiangsu Hengrui Medicine is forecast to grow earnings and revenue by 14.9% and 11.6% per annum respectively. EPS is expected to grow by 14.5% per annum. Return on equity is forecast to be 14.1% in 3 years.

Key information

14.9%

Earnings growth rate

14.5%

EPS growth rate

Pharmaceuticals earnings growth18.0%
Revenue growth rate11.6%
Future return on equity14.1%
Analyst coverage

Good

Last updated21 Jan 2025

Recent future growth updates

Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Aug 23
Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Recent updates

Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?

Jan 19
Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?

Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult

Oct 25
Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult

Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Oct 07
Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Aug 23
Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price

Jul 03
Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price

Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

May 22
Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Apr 24
Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Earnings and Revenue Growth Forecasts

SHSE:600276 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202738,80411,4329,20910,2572
12/31/202634,3837,9916,6267,54921
12/31/202529,7486,5835,4096,36624
12/31/202427,1206,0364,1265,10224
9/30/202425,9955,4486,2827,920N/A
6/30/202425,2525,4266,3387,801N/A
3/31/202423,3254,4327,0248,684N/A
12/31/202322,8204,3026,1607,644N/A
9/30/202322,3444,2071,5593,387N/A
6/30/202322,2164,0951,7973,295N/A
3/31/202321,2893,909-3461,331N/A
12/31/202221,2753,906-7271,265N/A
9/30/202221,6523,4961,0382,908N/A
6/30/202222,8363,9821,1443,566N/A
3/31/202224,4554,2712,1024,168N/A
12/31/202125,9064,5302,5544,219N/A
9/30/202128,5206,2771,4232,944N/A
6/30/202129,7236,3344121,554N/A
3/31/202129,1376,5101,2902,088N/A
12/31/202027,7356,3282,8783,432N/A
9/30/202025,7575,8524,5745,195N/A
6/30/202024,5715,5775,1775,741N/A
3/31/202023,8495,4514,3884,933N/A
12/31/201923,2895,3283,2553,817N/A
9/30/201921,9044,8892,8313,332N/A
6/30/201919,6834,5682,4242,899N/A
3/31/201918,5284,3092,2592,706N/A
12/31/201817,4184,0662,2452,774N/A
9/30/201816,2283,8012,2042,336N/A
6/30/201815,2523,553N/A2,518N/A
3/31/201814,5233,354N/A2,433N/A
12/31/201713,8363,217N/A2,547N/A
9/30/201712,8962,988N/A2,928N/A
6/30/201712,1592,848N/A2,666N/A
3/31/201711,5942,716N/A2,630N/A
12/31/201611,0942,589N/A2,593N/A
9/30/201610,7092,529N/A2,653N/A
6/30/201610,2092,425N/A2,517N/A
3/31/20169,7812,309N/A2,444N/A
12/31/20159,3162,172N/A2,277N/A
9/30/20158,8331,970N/A2,021N/A
6/30/20158,3281,817N/A1,818N/A
3/31/20157,9351,673N/A1,695N/A
12/31/20147,4521,516N/A1,574N/A
9/30/20147,1561,429N/A1,497N/A
6/30/20146,7441,356N/A1,585N/A
3/31/20146,4431,292N/A1,320N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600276's forecast earnings growth (14.9% per year) is above the savings rate (2.8%).

Earnings vs Market: 600276's earnings (14.9% per year) are forecast to grow slower than the CN market (25% per year).

High Growth Earnings: 600276's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600276's revenue (11.6% per year) is forecast to grow slower than the CN market (13.3% per year).

High Growth Revenue: 600276's revenue (11.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600276's Return on Equity is forecast to be low in 3 years time (14.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 21:36
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Hengrui Medicine Co., Ltd. is covered by 62 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Changming HeBOCI Research Ltd.
Bo LiBofA Global Research